+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 15 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating a revised weight-based dose of tafenoquine target dose 7.5mgkg to treat patients with vivax malaria. This Phase 3 trial aims to determine if this revised regimen is not worse than a high dose of primaquine given over seven days and if it is better than the standard fixed dose of tafenoquine. The study also looks at how well patients tolerate the revised dose and whether it is practical to use. Participants will be randomly assigned to one of three groups. One group will receive a single weight-based oral dose of tafenoquine along with schizontocidal treatment. Another group will receive a single fixed oral dose of 300mg tafenoquine plus schizontocidal treatment. The third group will receive schizontocidal treatment plus a high dose of primaquine given orally over seven days. The trial will monitor safety and effectiveness over several months. During the study, participants will be followed for six months. Researchers will assess the occurrence of vivax parasitaemia at 4 and 6 months as the main outcome. Other measurements include symptomatic vivax parasitaemia, anemia incidence at different time points, hemoglobin changes, adverse events, and methemoglobin levels. Participants must provide informed consent and live in the study area to allow regular follow-up and monitoring throughout the trial.

Age: 18Years +All GendersPhase 3
4 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate targeting EGFR and HER3 with a chemotherapy payload, compared to treatment chosen by physicians including paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine for patients with first-line metastatic triple-negative breast cancer TNBC or low estrogen receptor ER-low, HER2-negative breast cancer who cannot receive anti-PDL1 or endocrine therapies. This study includes adults with locally advanced, recurrent inoperable, or metastatic disease who meet specific eligibility criteria. Participants are randomly assigned to receive iza-bren or one of the physicians choice chemotherapy regimens. The treatments are given at specified doses on scheduled days. The study includes two phases Phase 2 to determine the recommended dose of iza-bren and Phase 3 to compare progression-free survival and other outcomes. The study will last several years, with follow-up extending up to approximately 47 months after randomization. During the study, participants will undergo regular assessments including imaging scans to measure tumor response, laboratory tests, and monitoring for adverse events. Quality of life questionnaires will also be completed. Researchers will track progression-free survival, overall survival, treatment-related side effects, tumor size changes, and patient-reported outcomes to evaluate the treatments. The total participation duration may extend up to several years depending on treatment response and follow-up requirements.

Age: 18Years +All GendersPhase 2Phase 3
295 locations
R

Actively Recruiting

Researchers are evaluating the effects of the drug EYU688 compared with a placebo in adults aged 18 to 60 who have dengue fever. This study aims to understand how EYU688 influences dengue viral load, fever clearance time, and clinical symptoms. It is a phase 2 randomized, participant- and investigator-blinded, placebo-controlled trial with two parallel cohorts differing by pharmacokinetic sampling schedules. Participants will receive EYU688 or a matching placebo orally. The study includes two cohorts running simultaneously one with intensive pharmacokinetic sampling and one with sparse sampling, to assess the drugs behavior in the body. Treatment is administered during the initial days following fever onset, with careful monitoring of viral load and clinical signs. Throughout the study, participants will undergo regular assessments including viral load measurements, fever monitoring, clinical symptom evaluations, and laboratory tests such as blood counts and liver enzyme levels. Safety monitoring for adverse events will continue through Day 35. The primary outcome is reduction in viral load at 48 hours after treatment start. The total trial period includes follow-up until Day 35, with ongoing evaluation of clinical recovery and safety.

Age: 18Years - 60YearsAll GendersPhase 2
27 locations
A

Actively Recruiting

Researchers are investigating whether patients with locally advanced cervical cancer who still have detectable cell-free human papillomavirus DNA cfHPV-DNA in their plasma after standard treatment may benefit from additional chemotherapy. This trial is a prospective, randomized, multicenter clinical study designed to evaluate adjuvant chemotherapy based on this biomarker. The study focuses on patients who have undergone chemoradiotherapy and have persistent cfHPV-DNA, as this may indicate ongoing disease activity. Participants first receive standard treatment with concomitant chemoradiotherapy, including doses of radiation and weekly cisplatin. Four weeks after completing this treatment, a blood test is conducted to detect cfHPV-DNA in plasma. Patients with positive cfHPV-DNA results are randomly assigned to either receive two additional cycles of adjuvant chemotherapy with cisplatin and gemcitabine or to be monitored without further chemotherapy. Patients in both groups undergo regular follow-up every four months, including plasma cfHPV-DNA testing, CT scans of the chest, MRI scans of the abdomen and pelvis, and clinical and gynecological exams. During the study, participants are closely monitored for progression-free survival, overall survival, treatment response, quality of life, and any toxic effects of treatment. Follow-up assessments occur at regular intervals from 7 to 120 days after treatment. The total duration of participant involvement varies based on follow-up schedules. The study uses a single-blind design and randomized allocation to ensure scientific rigor while maintaining patient safety throughout the trial period.

Age: 18Years - 70YearsFEMALEPhase 3
26 locations
C

Actively Recruiting

Researchers are evaluating how well zenagamtide works and how safe it is compared to insulin glargine in people with type 2 diabetes who have a higher risk of heart and blood vessel problems. This study includes participants already taking 1 to 3 diabetes medications and aims to see if zenagamtide is not worse than insulin glargine in controlling blood sugar levels over one year. Participants are randomly assigned to receive either zenagamtide or insulin glargine. Zenagamtide is given once weekly as an injection under the skin in the thigh, abdomen, or upper arm using a pre-filled pen injector. Insulin glargine is given once daily as a subcutaneous injection in the same body areas, with rotation of the injection site. The study lasts for at least 52 weeks for primary outcomes, with cardiovascular events monitored for 104 weeks or more. During the study, participants will have regular assessments including blood tests for HbA1c, body weight measurements, waist circumference, blood pressure, cholesterol levels, and markers of inflammation. The main measure is the change in blood sugar control after 52 weeks. The study also tracks heart-related events and other health changes over two years. Participants will be monitored closely throughout the study period to evaluate safety and treatment effects.

Age: 45Years +All GendersPhase 3
330 locations
P

Actively Recruiting

Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.

Age: 18Years +All GendersPhase 3
804 locations
S

Actively Recruiting

Researchers are evaluating DA-020 as a treatment to prevent hair loss caused by chemotherapy, a common and distressing side effect especially for women with breast cancer. This study aims to test whether DA-020, a topical formula containing an 1 agonist, can reduce scalp blood flow and thereby minimize chemotherapy-induced alopecia. The trial is sponsored by Applied Biology, Inc. and focuses on patients with early-stage breast cancer undergoing taxane andor anthracycline chemotherapy. Participants will be randomly assigned to one of three groups topical DA-020 solution, topical placebo solution, or a combination of DA-020 with Hyperforin 1.5%. Each active treatment involves applying 7 mL of the solution to the scalp. The study is designed as a randomized, quadruple-masked trial with parallel groups. The main treatment period lasts 12 weeks, with additional follow-up up to 24 weeks to assess hair regrowth. During the trial, participants will be monitored regularly for hair loss prevention using standardized criteria. Researchers will assess hair loss at baseline and throughout the 12-week treatment and evaluate hair regrowth up to 24 weeks after treatment start. Safety and adherence will be tracked along with any side effects. The total study duration spans from May 2026 to March 2027, including screening, treatment, and follow-up phases.

Age: 18Years - 65YearsFEMALEPhase 1Phase 2
2 locations
E

Actively Recruiting

Researchers are studying the effectiveness, safety, and tolerability of different antiretroviral therapy ART regimens in people with HIV-1 who are also receiving rifampin-based treatment for tuberculosis TB. This Phase IIIb international trial compares two dual therapy regimens using dolutegravir and lamivudine with the standard three-drug ART regimen in individuals who have not previously received ART. The study addresses the high global burden of TB among people with HIV and explores starting ART alongside TB treatment to improve survival. Participants will be randomly assigned to one of three groups Arm 1 receives a twice-daily fixed-dose combination of dolutegravir 50mg and lamivudine 300mg during TB therapy and for two weeks after, then once daily up to week 52 Arm 2 receives the same combination once daily in the morning plus dolutegravir 50mg in the evening during TB therapy and for two weeks after, then once daily to week 52 Arm 3 follows the local standard of care with dolutegravir 50mg plus tenofovir disoproxil fumaratelamivudine once daily during and after TB therapy. Treatment continues for 52 weeks in all arms. During the study, participants will have their HIV viral load and CD4 cell counts monitored at 28 and 48 weeks to assess virologic suppression and immune response. Additional evaluations include measuring drug concentrations and monitoring adverse events over two years. The primary outcome is the proportion of participants achieving HIV-1 virologic suppression at 28 weeks. The trial involves regular visits and medical assessments to ensure safety and treatment adherence throughout the study period.

Age: 15Years - 99YearsAll GendersPhase 3
5 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating how well long-acting lenacapavir works to prevent HIV infection in people at higher risk in Brazil. The study aims to assess safety, continued use over time, and participant preference compared to daily oral pre-exposure prophylaxis PrEP. It focuses on how many participants get HIV while using lenacapavir, its safety in real-world health settings, and factors affecting ongoing prevention use. Participants can choose between two prevention options injections of long-acting lenacapavir under the skin every six months or daily oral PrEP pills containing tenofovir disoproxil fumarate and emtricitabine. Those choosing lenacapavir receive an oral loading dose followed by subcutaneous injections at enrollment and every six months, up to four injections during follow-up. Those choosing oral PrEP take daily pills with regular medication dispensing and follow-up visits. Both groups receive prevention counseling, regular HIV testing, and screening for sexually transmitted infections and viral hepatitis. Participants will visit clinics regularly for HIV testing, health checkups, and safety monitoring. They will answer questions about their health, medication use, and experiences, while researchers evaluate adherence, injection site reactions, and adverse events. The study will track persistence on lenacapavir over 24 months and time to discontinuation. This research will help health services understand how to offer and support long-acting HIV prevention in Brazil, with follow-up lasting up to two years.

Age: 16Years - 30YearsAll GendersPhase Not Applicable
8 locations

1-10 of 15

1